Form 4: Supernus Officer's RSU Vesting and Tax Withholding

Supernus Pharmaceuticals' SVP, Chief Technology Operations Officer, Frank Mottola, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Summary

• Frank Mottola, SVP, Chief Technology Operations Officer at Supernus Pharmaceuticals, reported transactions on February 25, 2026.
• He acquired 1,875 shares of common stock upon the vesting of restricted stock units.
• Concurrently, 977 shares of common stock were disposed of by the company to satisfy tax withholding obligations related to the RSU vesting, at a price of $50.69 per share.
• Following these transactions, Mottola beneficially owns 18,106 shares of common stock directly.
• He also beneficially owns 1,875 restricted stock units directly, which are settled in common stock upon vesting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation and continued insider ownership, with no significant strategic implications.

Positives

• Vesting of 1,875 restricted stock units indicates a compensation event for the officer, aligning executive incentives with company performance.
• The officer's continued beneficial ownership of 18,106 common shares and 1,875 restricted stock units demonstrates ongoing alignment with shareholder interests.

Negatives

• A disposition of 977 common shares occurred to cover tax withholding, resulting in a reduction of the officer's direct common stock holdings.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

StockSavvy.ai notes that insider transaction filings like this Form 4 are routine disclosures for executive compensation events, providing transparency into management's equity holdings and compensation structure within the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries, including pharmaceuticals.
• The RSU vesting and subsequent tax withholding are common practices for executive compensation, aligning with typical equity incentive plans seen in comparable biotech and pharmaceutical companies.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and insider ownership, which can influence investor confidence.
• Employees: Reflects standard executive compensation practices, potentially impacting morale and retention strategies for key personnel.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving RSU vesting and tax-related share withholding. It does not present new information that would fundamentally alter the investment thesis for Supernus Pharmaceuticals, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Compensation, Executive Compensation, Frank Mottola